Biomarkers that influence clinical management include IDH mutations, combined with loss of chromosome arms 1p and 19q, leading to a diagnosis of oligodendroglioma that responds well to PCV, whereas methylation of the MGMT promoter in glioblastoma predicts a better response to TMZ [50–52]. This evidence concerns the gene MGMT and oligodendroglioma.